Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
162 USD | +3.50% | +9.05% | -10.17% |
05-02 | Amgen Posts Higher 1Q Revenue, Swings to Loss | DJ |
04-23 | Sector Update: Health Care Stocks Rise in Afternoon Trading | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 5.03 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.17% | 16.94B | B | ||
-1.65% | 103B | B+ | ||
+6.75% | 101B | B+ | ||
+5.71% | 23.07B | B | ||
-12.60% | 22.23B | B+ | ||
-9.70% | 18.05B | A- | ||
-39.98% | 17.18B | A- | ||
+6.12% | 14.07B | C+ | ||
+35.47% | 12.35B | C+ | ||
+307.09% | 8.35B | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BGNE Stock
- Ratings BeiGene, Ltd.